At a glance
- Originator Merck & Co
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemic heart disorders; Thrombosis
Most Recent Events
- 01 May 1998 New profile
- 01 May 1998 Preclinical development for Ischaemic heart disorders in USA (PO)
- 01 May 1998 Preclinical development for Thrombosis in USA (PO)